IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
about
Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo.Gene-modified bone marrow cell therapy for prostate cancer.Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer.Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
P2860
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@ast
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@en
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@nl
type
label
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@ast
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@en
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@nl
prefLabel
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@ast
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@en
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@nl
P2093
P356
P1433
P1476
IL-12 gene-modified bone marro ...... al metastatic prostate cancer.
@en
P2093
Brenner MK
Naruishi K
Thompson TC
P2888
P304
P356
10.1038/SJ.CGT.7701069
P577
2007-07-13T00:00:00Z